Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) EBIT Margin (2018 - 2025)

X4 Pharmaceuticals' EBIT Margin history spans 6 years, with the latest figure at 922.86% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 156773.0% year-over-year to 922.86%; the TTM value through Dec 2025 reached 247.44%, up 117614.0%, while the annual FY2025 figure was 247.44%, 117614.0% up from the prior year.
  • EBIT Margin reached 922.86% in Q4 2025 per XFOR's latest filing, up from 1558.58% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 12629.31% in Q2 2024 to a low of 6160.71% in Q3 2024.
  • Average EBIT Margin over 4 years is 963.53%, with a median of 973.49% recorded in 2022.
  • The largest YoY upside for EBIT Margin was 460213bps in 2025 against a maximum downside of -1395886bps in 2025.
  • A 4-year view of EBIT Margin shows it stood at 2235.75% in 2022, then increased by 18bps to 2642.38% in 2023, then plummeted by -194bps to 2490.59% in 2024, then surged by 63bps to 922.86% in 2025.
  • Per Business Quant, the three most recent readings for XFOR's EBIT Margin are 922.86% (Q4 2025), 1558.58% (Q3 2025), and 1329.55% (Q2 2025).